Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of neurological and inflammatory diseases with unmet medical needs. The company is actively engaged in scientific licensing and new drug development under the “RESEARCH and DEVELOPMENT” model. This model is executed by a highly capable and experienced multi-functional team of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts.
We integrate subject matter expertise, patent and licensing strategy in product development not only through rigorous project management but also from early stage projects to lifecycle management. We select drug candidates with strong scientific rationale and high feasibility of technical success, and progress them into highly differentiated products. Several novel new drug products with global market potential developed by Lumosa are available for collaboration in clinical trials, product development and for commercialization.
LT1001 is the first long-acting intramuscular analgesic injection containing nalbuphine sebacate, a prodrug of nalbuphine, in an oil-based formulation intended for sustained release of the drug. Nalbuphine is a κ-agonist / partial μ-antagonist analgesic with an analgesic effect comparable to that of morphine, yet it has a ceiling effect on respiratory depression. LT1001 was designed to take advantages of nalbuphine’s safety profile, and overcome the disadvantage of nalbuphine’s relatively short half-life. While most pain medications relieve pain for 2 to 6 hours, LT1001 exerts its analgesic effect for up to a week. In a post-operative setting, it will greatly increase pain patients’ quality of life, reduce healthcare resource, thus deliver a high pharmaco-economic value. The NDA for LT1001 was approved for post-surgical analgesia by the Taiwan FDA in Q1 2017, and the product launch is planned in Q2 2017 in Taiwan.
LT3001 is composed of peptide and small molecule. Peptide moiety is modified form the degradation products of fibrinogen to induce thrombolysis and dissolve blood clot without impairing hemostasis and causing devastating hemorrhage side effect. The small molecule portion of LT3001 is an antioxidant designed to limit oxidative stress and protect tissues from reperfusion injury.
During the acute stroke, oxidative stress culminates due to an imbalance between prooxidants and antioxidants and consequent excessive production of reactive oxygen species may mediate damage to cell structures, including lipids, membranes, proteins, and DNA. The oxidative stress induced cerebral vascular damage plays a critical role in the pathogenesis of ischemic brain injury following an ischemic insult. LT3001, by combining the thrombolysis and neuroprotection, holds promise as a safer and efficacious therapy for the treatment of acute ischemic stroke. The IND application planned in the US in 2017.